InMed Pharmaceuticals (INM) has released an update.
InMed Pharmaceuticals has announced their new oral drug candidate, INM-901, showing promise in treating Alzheimer’s by achieving similar brain drug concentration levels as intraperitoneal injection. The oral formulation could offer a more accessible and cost-effective treatment option, potentially reducing the side effects and treatment burdens of current intravenous Alzheimer’s therapies.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
